Protein quality in Mirasol Pathogen Reduction Technology treated apheresis derived FFP

被引：0
|
作者：
Smith, James W. [1 ]
Rock, G.
Buytaert-Hoefen, Kimberley
Hendrix, B.
Bihm, D.
Goodrich, R. [2 ]
机构：
[1] Oklahoma Blood Inst, Oklahoma City, OK USA
[2] LLC, Navigant Biotechnol, Lakewood, CO USA
来源：
TRANSFUSION | 2008年 / 48卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：146A / 146A
页数：1
相关论文
共 50 条
  • [1] Evaluation of the quality of Apheresis platelets treated with Mirasol® pathogen reduction technology
    Eakins, E.
    Murphy, C.
    Croxon, H.
    Birhire, R.
    Flynn, N.
    Taylor, S.
    Murphy, W.
    [J]. TRANSFUSION, 2008, 48 (02) : 21A - 21A
  • [2] Mirasol ® Pathogen Reduction Technology treated FFP maintains protein quality after 2 years in storage
    Buytaart-Hoefen, Kimberley
    Hendrix, B.
    Bihm, D.
    Gampp, D.
    Miklauz, M.
    Goodrich, R.
    [J]. TRANSFUSION, 2008, 48 (02) : 145A - 146A
  • [3] Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma
    Smith, James
    Rock, Gail
    [J]. TRANSFUSION, 2010, 50 (04) : 926 - 931
  • [4] Mirasol pathogen-reduced FFP maintains protein quality
    Buytaert-Hoefen, K. A.
    Hendrix, B. K.
    Gampp, D.
    Bihm, D. J.
    Goodrich, R. P.
    [J]. TRANSFUSION, 2007, 47 (03) : 73A - 73A
  • [5] Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS plus apheresis platelets
    Mastroianni, Maria Adele
    Llohn, Abid Hussain
    Akkok, Cigdem Akalin
    Skogheim, Ruby
    Odegaard, Elna Rathe
    Nybruket, Monica Jenssen
    Flesland, Annika
    Mousavi, Seyed Ali
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (02) : 285 - 290
  • [6] Effect of mirasol pathogen reduction technology system on immunomodulatory molecules of apheresis platelets
    Valsami, S.
    Grouzi, E.
    Mochandreou, D.
    Pouliakis, A.
    Piroula-Godoy, M.
    Kokori, S.
    Pittaras, T.
    Raikou, A.
    Politou, M.
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (01)
  • [7] QUALITY CONTROL OF FIBRINOGEN CONCENTRATE FROM PLASMA TREATED IN MIRASOL® PATHOGEN REDUCTION TECHNOLOGY
    Lachert, E.
    Kubis, J.
    Antoniewicz-Papis, J.
    Rosiek, A.
    Potocka, E.
    Poglod, R.
    Letowska, M.
    [J]. VOX SANGUINIS, 2013, 105 : 154 - 154
  • [8] Neutrophil Priming Activity in Platelet Concentrates (PCs) Collected by Apheresis and Treated with Mirasol® Pathogen Reduction Technology (PRT)
    Ambruso, D. R.
    Thurman, G.
    Tran, K.
    Marschner, S.
    Goodrich, R. P.
    [J]. TRANSFUSION, 2009, 49 : 9A - 9A
  • [9] COAGULATION POTENTIAL OF MIRASOL PATHOGEN REDUCTION TECHNOLOGY TREATED PLATELETS
    Marschner, S.
    Hovenga, N.
    Goodrich, R.
    [J]. VOX SANGUINIS, 2010, 99 : 247 - 248
  • [10] Analysis of plasma ratio and cell quality of platelet hyperconcentrates treated with mirasol® pathogen reduction technology
    Marschner, S.
    Buytaert-Hoefen, K. A.
    Hovenga, N. A.
    Dumont, D. F.
    Herschel, L. H.
    Roger, J.
    Dumont, L. J.
    Aubuchon, J. P.
    Goodrich, R. P.
    [J]. TRANSFUSION, 2007, 47 (03) : 81A - 81A
12345